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Clinical ischemia related events (PTCA, CABG, Ml, unatable AP and death),
and anti-anginal medications were reported affar 1 month placebo. Baseline
parameters were comparable between the groups. During the 1 month sin-
gle blind placebo period, 10 ischemia related events were reported (placabo
n = 1 and captopril n = 9, (–p < 0.05, placebo vs captopril). Anti-anginal
medication was prescribed in 6 (50A)and 13 (14%) patients, resp. (p c 0.05,
placebo vs captopril). It is concluded that, after atopping captopril, more is-
chemic evants and increased use of anti-anginal medication were reported
then in the placebo group, suggesting a rebound phenomenon.
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El7874 Level of Anticoagulation Achieved in Myocardial
Infarction Patienta Following Chronic Administration
of Fixed, Low-Doae Waffarin Therapy: Reaults from
the Coumadin Aspirin Reinfarction Study (CARS)
R.A. Barrington, S. Berkowitz, M. McDougal, C.M. O’Connor, A. Lenger,
P.T.O’Gare, S.L. Kopecky, .LM. Sutton, J. Hairier, R. Lee, J.M. Feyzi,
L. Jett, R.M. Califf, V. Fuster for the CARS Investigators. Duke C/irrica/
Research Institute, Durham, NC, USA
CARS teeted the hypothesis that the combination of aspirin and fixed, low-
doae warfarin would be euperior to aepirin in preventing death, reinfarction
and stroke following a myoeardial infarction (Ml). Patienta wera randomized
3-21 daya post Ml to one of three treatment arms: aspirin l&I mg (Group
A), warfarin 1 mg + aepirin 80 mg (Group B), warfarin 3 mg + aspirin 80 mg
(Group C). Patients received a double loading dose on the first two days.
At each visit (weeka 1-4, 6, 12, every 12) citrated whole blocd was shippad
overnight to a central laboratory where a prothrombin time waa reported
as an International Normalized Ratio (INR). Blinded dose reduction were
made for an INR 23.5 on two consecutive measures. Median (25, 75) INRs
by treatment groups:
Visit GroupA GroupB GroupC
(n= 2835) (n= 2028) (n= 2829)
Week1 1.03(0,99,1.07) 108 (1.01, 1.12) 1.54(1.24,2.17)
Week2 1.03(0.99,1.07) 1.08(1.02,1.12) 1.48(1.20,2.17)
Week3 1.03(0.98,1.07) 1.05(1.01,1.12) 1,38(1.18,1.90)
Week8 1.02(0.98,1.08) 1,05(1.01,11) 1.22(1.10,1.53)
Month12 1.02(0,98,1.08) 1.04(1.00,1.10) 1.20(1.08,1,50)
A steady state INR was reached and maintained by week six with the
majority of patients having INRaconsiderably leas than the standard level of
anticoagulation typically used in clinical practice (INR 2.0+3.0). The low level
of anticoagulation obtained may in part explain the equivalence in outcomes
among the treatment arms in CARS.
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1787-5]lnflUenCeOfHYW~ensionand~,oodpressure~n
the Suwival Benefit of ACE Inhibition After Acute
Myocardial Infarction
L. Kaber, C. Torp-Pedereen, M. Ottesen, H, Burchardt for the TRACE atudy
group. Dept. of Cardiology, Gentofle University Hospital, Denmark
Low blood pressure following an Acuta Myocardial Infarction is a relative
contraindication for ACE inhibition. We studied interrelation of the beneficial
effect of ACE inhibition with blood preasure at start of treatment and a diag-
noeiaof hypertension in the Trandolaprfl Cardiac Evaluation (TRACE) study.
Methods: In TRACE 1749 patients with moderate to aevere left ventricular
dysfunction (wellmotion indexs 1.2)ware randomieedtolong-term treatment
with the ACE inhibitor trandolapril or placebo. Ovarall the mottality reduction
of trandolapril was 22Y0.At randomisation 283 patients had syatolic bled
preasure (SBP) s 100,427 had SBP 101-110,428 had SBP 111-120,459
had SBP 121-140 and 174 had SBP >140. A histoty of hypertension was
present in 400 patients. Calculations are based on Cox propotiional hazard
medals and wall motion index, hearl failure, gender, aga and thrombolysis
are included ad confounding factora in the models. Results:
Subgroup RiskReductionwithTrandolapril
No diagnoaisof hvvarlension 0.9(0.75-1.1)
Diagn;aia of hypitiension 0.8 (OAS-0J35)
SBP <100 1.0 (0.7-1.5)
SBP 101-110 0.S8 (0.85-1.2)
SBP111-120 0.78 (0.55-1.0)
SBP 121-140 0,SS (0.85-1.2)
SSP>140 0.57(0.35-0.92)
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Mortality Rate After Myocardial Infarction Equally
Increaeed in Diabetic Patients Treated with Oral
Antidiabetic Agents and Insulin
P.Hildebrandt,M. Saibek, L. K@ber,C. Torp-Pedereenforthe TRACE
StudyGroup.Dept. of Cardiology Frederiksberg /-fospita/,Denmark, Dept.
of CardioIog~ Gentoffe Hospital, Denmark
Patients with diabetes havea poor prognosis after myocardial infarction (Ml).
However, the relation to different types of diabetic traatment, Ml complica-
tions and residual systolic function is uncertain. The aim of the present study
was a further evaluation of theee relationships. Methods: 5960 patients with
confirmed Ml, surviving 2 days after admission were included in the study.
Preadmission medical history, including type of diabetic treatment, compli-
cations during hoapital stay and echocardiographic evaluation of ventricular
wall motion index (WMI) were obtained, as well as 3 year mortality data.
Resu/fs:% mortality
Non-diabetics Diet Tablets Insulin
Number 5387 173 319 125
1 year 17.0 24.3 29.2 29.6
2 year 23.2 34.3 42.8 41.7
3 year 28.8 41.7 53.7 51.6
By multivariateanalysisincludingage, sex, WMI, historyof hypertension
and perviousMl, diabetea was found to be an independentpradictorof
mortality(oddsratio1.488 (95% Cl: 1.221,814))
Conclusion: Patients with diabetes have a poor prognoais after Ml, with
a significant increased moflality rate, regardless of other risk factors. This
increased morlality is similar in patients treated with insulin and oral anti
diabetics agents.
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Improvement in Stunned and Hibernating
Myocardium in Patients with Coronary Artery
Disease (CAD) and Congestive Heart Failure (CHF)
F.Haas, C. Haehnel, N. Augustin, W. Pickeri, S. Nekolla 1, H. Meisner,
M. Schwaiger. Deutsches Herzzentrum Murrchen, German& 1 Technische
UrriversitatMiinchen, Germany
Ithas been demonstrated that NH3/FDG-positron emission tomography
(PET) predicts the recoveryof regional function of ischemically compromised
myocardium. The present study evaluated the time course and the extant of
improvement of “hibernating myocardium” (flow-metabolism-miamatch; HIB)
and of “stunned myocardium” (normal flow/metabolism but impaired func.
tion; STU). 26 patients with CAD and CHF (EF = 27%) were functionally
assesaad by 2-d echocardiography using a 5-point grading system from -1
(dyskinesia) to 3 (normal function) preoperatively, 10 days, 4 month and
one year after CABG, 213 revascularized free-wall LV-segments with wall
motion abnormalities were examined: 2S.2?4of the segmente displayed HIB,
while the remaining 71.6% STU, TendaysafterCABG 507. of HIB segments
regained normal to near normal function. Four months and one year after
CABG, however, 73.1% and 67% diaplayed this functional improvement. In
contrast, 76.5% of STU aegments regained normal to near normal function
after 10 days (p = 0005), after 4 month 84.8% (p = 0.01) and after 1 year
85.4% (n.a). The results suggast that in patients with marked LV-dysfunction
scintigraphic patterns of “atunning” are more pronounced than that of “hi.
bernation”. Preoperatively, “hibernating myocardium” displays more sevare
wall motion abnormalities with slower recovery; after one yaar, however,
the degree of functional improvement is similar in both aituationa. For early
racovery “stunned myocardium” appears to be more important.
Corrc/uaion:Thebeneficial effect of Trandolaprflseems to be more marked
in patients with a history of hypertension or a relative high blood pressure on
entry.
